Ambroxol	NN
hydrochloride	NN
in	IN
the	DT
management	NN
of	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
:	:
Clinical	JJ
trials	NNS
are	VBP
the	DT
need	NN
of	IN
the	DT
hour	NN
.	.

Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
is	VBZ
a	DT
debilitating	JJ
lung	NN
disease	NN
of	IN
unknown	JJ
etiology	NN
.	.

Its	PRP$
pathogenesis	NN
remains	VBZ
poorly	RB
elucidated	VBN
but	CC
aberrant	JJ
wound	NN
healing	NN
is	VBZ
central	JJ
to	TO
its	PRP$
pathology	NN
.	.

It	PRP
has	VBZ
a	DT
median	JJ
survival	NN
time	NN
of	IN
3	CD
to	TO
5	CD
years	NNS
.	.

None	NN
of	IN
the	DT
treatment	NN
modality	NN
or	CC
drugs	NNS
tried	VBD
in	IN
its	PRP$
management	NN
has	VBZ
so	RB
far	RB
changed	VBD
the	DT
overall	JJ
outcome	NN
.	.

Recent	JJ
in	FW
vitro	FW
and	CC
experimental	JJ
studies	NNS
have	VBP
shown	VBN
that	IN
ambroxol	NN
hydrochloride	NN
exerts	VBZ
several	JJ
newer	JJR
actions	NNS
,	,
namely	RB
the	DT
surfactant	JJ
stimulatory	JJ
,	,
anti-imflammatory	JJ
and	CC
anti-oxidant	JJ
actions	NNS
,	,
in	IN
addition	NN
to	TO
its	PRP$
being	VBG
a	DT
secrrtolytic	JJ
and	CC
mucokinetic	JJ
agent	NN
.	.

The	DT
anti	JJ
inflammatory	JJ
and	CC
anti-fibrotic	JJ
properties	NNS
of	IN
the	DT
drug	NN
are	VBP
due	JJ
to	TO
its	PRP$
ability	NN
to	TO
block	VB
the	DT
release	NN
of	IN
oxidant	JJ
stress	NN
markers	NNS
,	,
cytokines	NNS
,	,
leukotrienes	NNS
,	,
MPO	NN
activity	NN
,	,
hydroxyproline	NN
content	NN
,	,
nitic	JJ
oxide	NN
and/or	CC
collagen	NN
I	PRP
		VBP
III	CD
mRNA	NN
in	IN
the	DT
local	JJ
milieu	NN
while	IN
preserving	VBG
the	DT
SOD	NN
and	CC
GSH-PX	NN
activities	NNS
.	.

In	IN
human	JJ
studies	NNS
also	RB
,	,
the	DT
agent	NN
was	VBD
able	JJ
to	TO
block	VB
the	DT
expression	NN
of	IN
TGF-beta	NN
and	CC
TNF-alpha	NN
in	IN
plasma	NN
and	CC
preserving	VBG
the	DT
carbon	NN
monoxide	NN
diffusion	NN
capacity	NN
of	IN
the	DT
lungs	NNS
in	IN
lung	NN
cancer	NN
patients	NNS
on	IN
radiation	NN
therapy	NN
.	.

Thus	RB
,	,
ambroxol	NN
may	MD
have	VB
the	DT
potential	JJ
to	TO
check	VB
the	DT
dysregulated	VBN
healing	NN
process	NN
that	WDT
is	VBZ
typical	JJ
of	IN
IPF	NN
.	.

This	DT
,	,
coupled	VBN
with	IN
its	PRP$
safety	NN
profile	NN
for	IN
human	JJ
use	NN
,	,
warrants	NNS
clinical	JJ
trials	NNS
of	IN
the	DT
drug	NN
in	IN
the	DT
management	NN
of	IN
IPF	NN
.	.

